Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PEOPLE - Bioheart (US) makes appointments:

This article was originally published in Clinica

Executive Summary

Bioheart (Weston, Florida), a discoverer, developer and commercialiser of cellular-based products, has strengthened its management team with several new appointments, three of whom, Manny Villafana, Richard Spencer and Norman Dann, have been appointed to the board. Mr Villafana is a former executive of Medtronic and founder of Cardiac Pacemakers (now part of Guidant CRM), St Jude Medical and ATS Medical. Mr Spencer, is the former president of the marketing division of Cordis (now Cordis Johnson & Johnson) and vice-president of Cordis Dow, will also serve as a consultant to Bioheart. Mr Dann, who has over 40 years of industry experience, is a former board member, director and consultant for World Medical Manufacturing Corporation (now Medtronic AVE World Medical).

You may also be interested in...

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts